CYP19A1 and breast carcinoma: Our results are in agreement with those of large meta-analyses of hormone-related genetic variants and breast cancer risk (which included over 10,000 cases and 10,000 controls) that did not observe an association for SHBG rs6259, PGR rs1042838, CYP19 rs10046 and rs4775936, or UGT1A1 rs8175347 variants [32], [44].